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Emerging Therapies for Hepatitis C
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The combination of pegylated interferon (PEG-IFN) and riba-
virin (RBV), the current therapy for hepatitis C virus (HCV) 
infection, has saved the lives of many HCV-infected patients. 
Direct-acting antivirals (DAAs) target several sites of HCV 
nonstructural proteins, resulting in the cessation of viral 
replication. The first NS3/4A protease inhibitors consisted 
of boceprevir and telaprevir, which have shown superior ef-
ficacy against genotype 1 HCV infection when combined with 
PEG-IFN/RBV compared with the standard therapy in both 
treatment-naive and -experienced patients. Simeprevir, falda-
previr, and asunaprevir are second-wave, first-generation 
NS3/4A inhibitors that have already been or will soon be ap-
proved. Second-generation protease inhibitors are in clinical 
trials. Daclatasvir is the first approved DAA belonging to the 
class of NS5A replication complex inhibitors. The potency 
of daclatasvir is very high, and this drug is an important 
and essential component of combination regimens for all 
genotypes. Sofosbuvir, the first approved NS5B polymerase 
inhibitor, is characterized by high potency and genetic barri-
ers to resistance. Sofosbuvir combined with RBV achieved 
an interferon-free regimen in genotype 2 or 3 patients with a 
reduced treatment duration. It can also be used in combina-
tion with PEG-IFN/RBV in genotype 1 patients for 12 weeks. 
DAAs have provided new hope for curing HCV infections with 
a short treatment duration and acceptable adverse events. 
(Gut Liver 2014;8:471-479)
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INTRODUCTION
Hepatitis C virus (HCV) infection globally presents a serious 
health burden. Approximately 3% of the population is known 
to be infected with HCV worldwide and the prevalence differs 
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even among Asia-Pacific countries, from 1% to 2% in most 
areas to 15.6% in Mongolia.1-3 Although there is a controversy 
on the natural course of chronic hepatitis C (CHC),4 a third of 
those infected with HCV are estimated to develop cirrhosis 
within 20 years.5 Data have shown that eradication of HCV by 
antiviral treatment could prevent histological deterioration and 
result in improvement of liver histology,6 as well as reduction 
in liver-related morbidity and mortality.7 The combination of 
pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has been 
a standard of care for the management of CHC and this regimen 
significantly contributed to improvement of long-term clinical 
outcomes of treated patients. Nevertheless, the rate of treatment 
success defined by sustained virologic response (SVR) is just 
40% to 50% in genotype 1 infection.8 Because of the adverse 
events and discomforts by administration of PEG-IFN and RBV, 
frequent dose reduction and discontinuation resulting in intoler-
ance and treatment failure are also disadvantages of the current 
therapy for hepatitis C. Other shortcomings of PEG-IFN/RBV 
therapy are that HCV eradication is hardly expected in patients 
with high baseline viral loads, older age, advanced fibrosis and 
high body mass index.9
In HCV treatment, a substantial progress has been made after 
development of the first two NS3/4A oral protease inhibitors, 
boceprevir (BOC) and telaprevir (TVR), which were recently ap-
proved for use in combination with PEG-IFN/RBV. The so-called 
direct-acting antiviral (DAA) opened a new era for the possibility 
of interferon-free therapy, lower pill-burden, increased treatment 
success rate as well as reduced duration of therapy. Multiple, 
concomitant clinical trials of new DAAs being conducted repre-
sent a fast and extensive research for anti-HCV treatment. Be-
sides the HCV proteins such as NS3/4A, NS5A, NS5B as targets 
of therapy, therapeutic vaccines, drugs targeting host protein, 
other kinds of interferon are also under development. In this 
review, we aim to summarize the advantages and limitations of 
the currently available DAAs, new DAAs in clinical trials.
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CLASSIFICATION OF DAAs
The targets of currently approved or in development are re-
lated with HCV replication, specifically translation and polypro-
tein processing (NS3/4A), HCV genome replication (NS5B poly-
merase and NS5A), and viral assembly (NS5A).10 Inhibition of 
NS3 (serine protease) and its cofactor, NS4A, results in blocking 
proteolytic maturation of a large portion of the nonstructural 
region of the HCV polyprotein, NS3 to NS5B. BOC and TVR are 
the first NS3/4A protease inhibitors approved for the treatment 
of genotype 1 infection. A number of other protease inhibitors, 
which have been developed and in phase II or III clinical trials, 
are classified as “first-generation” and “second-generation” ac-
cording to degree of genetic barrier to resistant HCV and geno-
type coverage. The first-generation protease inhibitors include 
BOC, TVR, simeprevir (TMC-435), faldaprevir (BI201335), vani-
previr (MK-7009), and asunaprevir (BMS-650032). The second-
generation protease inhibitors, characterized by potent activity 
against pan-genotypes and high genetic barrier to resistance, 
include MK-5172 and ACH-2684 in phase II clinical trial. NS5A 
is a dimeric protein required for HCV RNA replication and vi-
rion assembly.11 NS5A inhibitors have potent antiviral activity, 
but the genetic barrier to resistance is low. Daclatasvir (BMS-
790052), GS-5885, ABT-267, PPI-668 are included in NS5A 
inhibitors. The NS5B, RNA-dependent RNA polymerase (RdRp), 
is an attractive target for anti-HCV therapy since this enzyme 
is directly responsible for the HCV RNA genome synthesis. As 
RNA chain terminators, NS5B polymerase inhibitors are clas-
sified into nucleos(t)ide inhibitors (NIs) and nonnucleos(t)ide 
inhibitors (NNIs) according to the structures. NIs have potent 
antiviral activity across all HCV genotypes and have high ge-
netic barrier to resistance. Sofosbuvir (SOF) (GS-7977), which 
has recently been approved as “interferon-free” drug by Food 
and Drug Administration (FDA) in the United States, is the most 
advanced NI. Mericitabine (RG7128) and VX-135 are other NIs 
in phase II clinical trials. Owing to binding to less conserved 
sites on NS5B, NNIs do not have antiviral activity against pan-
genomic HCV and have low genetic barrier to resistance. Sev-
eral NNIs including ABT-333, ABT-072, BI207127 are being 
evaluated in combination with other antiviral agents. Table 1 
summarizes the structural characteristics, potency and genetic 
barrier of each DAA approved or in clinical trials.
NS3/4A INHIBITORS
1. Boceprevir
BOC is now an approved NS3/4A inhibitor for the treatment 
of genotype 1 HCV infection at a dose of 800 mg, 3 times in 
Table 1. Classes and Characteristics of Direct-Acting Antivirals
Class
Structural, functional 
characteristics
Potency
Genetic barrier to 
resistance
Compound
Current 
status
NS3/4A protease inhibitors Inhibiting proteolytic maturation of
   First-generation HCV polyprotein High in G1 Low to medium Boceprevir Approved
Covalent linear inhibitors Low in G2/3 Telaprevir Approved
Noncovalent linear inhibitors Simeprevir (TMC-435) Approved
Macrocyclic inhibitors Faldaprevir (BI201335) Phase III
Asunaprevir (BMC-650032) Phase III
Danoprevir (RG7227) Phase II
Vaniprevir (MK-7009) Phase III
   Second-generation High in all G Medium MK-5172 Phase II
ACH-2684 Phase II
NS5A inhibitors Biding to domain I of NS5A, resulting High Low to medium Daclatasvir Phase III
in the suppression of RNA synthesis GS-5885 Phase III
ABT-267 Phase III
PPI-668 Phase II
NS5B polymerase inhibitors
   Nucleos(t)ide inhibitors Mimics of natural polymerase High in all G Medium to high Sofosbuvir Approved
substrates. Incoporated in the RNA Mericitabine (RG7128) Phase II
leading to chain termination VX-135 Phase II
   Nonnucleos(t)ide inhibitors Binding to the surface of NS5B enzyme Medium to Low ABT-333 Phase III
High BI207127 Phase III
ABT-072 Phase II
HCV, hepatitis C virus.
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combination with PEG-IFN/RBV.12 In a randomized, multicenter 
phase II trial (SPRINT-1), BOC combined with PEG-IFN/RBV 
for 24 weeks after lead-in PEG-IFN/RBV for 4 weeks in geno-
type 1 achieved 56% of SVR rates, which were significantly 
higher than 38% in control group (PEG-IFN/RBV for 48 weeks). 
When duration of triple therapy was extended to 44 weeks 
after 4-week of PEG-IFN/RBV lead-in therapy, the SVR rates 
increased to 75%. Interestingly, virologic response during the 
lead-in period guided the duration of triple therapy; patients 
achieving less than 1.5 log10 reduction in viral levels after lead-
in could benefit from duration of a total 48 weeks, while those 
with greater than 1.5 log10 reduction had similar SVR rate re-
gardless of treatment duration of 28 weeks or 48 weeks.13 The 
most common adverse event of BOC was found to be anemia, 
which appeared to contribute to higher discontinuation rate 
of BOC-containing antiviral treatment (9% to 19%) compared 
with control group (8%). A phase III trial of BOC (SPRINT-2) 
including 938 nonblack patients highlighted the importance 
of response-guided therapy (RGT). The rates of SVR in patient 
who received 24 weeks of triple therapy after 4 weeks of lead-
in period, and achieved undetectable HCV RNA at week 8 
through week 24, was 97%, which was comparable with 96% in 
patients who received 44 weeks of triple therapy and a total of 
48 weeks of therapy. Additional PEG-IFN/RBV after 24 weeks 
of triple therapy was not helpful in patients in whom HCV RNA 
levels were still detectable at week 8, since there was no differ-
ence of SVR rate (74%) between patients who received PEG-
IFN/RBV for 20 weeks more and those who did not.14 BOC has 
been shown to increase SVR rates in retreatment for genotype 1 
HCV-infected patients who failed previous PEG-IFN/RBV thera-
py. In a randomized trial (RESPOND-2), BOC for 32 weeks or 44 
weeks in combination with PEG-IFN/RBV after 4 weeks of lead-
in period of PEG-IFN/RBV resulted in the SVR rates of 59% and 
66%, respectively, which were significantly higher than 21% in 
48 weeks of PEG-IFN/RBV (control).15 Anemia was also more 
common adverse event in BOC-based treatment than in the con-
trol. Retreatment with BOC-based regimen was more effective 
in patients who showed relapse or partial response to previous 
standard therapy than those who showed prior null response. In 
a study of 168 patients in control arms of BOC phase II/III trials 
who did not achieve treatment success, SVR rates after retreat-
ment with triple therapy were 41%, 67%, and 96% in prior null 
responders, partial responders, and relapsers, respectively.16
Advanced fibrosis or cirrhosis related to HCV infection is 
the most urgent indication of antiviral therapy since the risk 
of hepatic decompensation or development of hepatocellular 
carcinoma is high. Furthermore, several studies have reported 
that achievement of SVR in patients with compensated cir-
rhosis could prevent disease progression and lead to improved 
survival.17,18 The number of cirrhotic patients in clinical trials 
is limited, thus, the efficacy or safety of BOC is uncertain in 
these patients. In a study of 178 genotype 1 HCV patients with 
Metavir F3 or F4 who participated in the two pivotal BOC tri-
als (SPRINT-2 and RESPOND-2),14,15 the overall SVR rates was 
11% to 33% in F3 patients and 10% to 14% in F4 patients who 
received BOC-based response guided therapy or BOC/PEG-IFN/
RBV for 44 weeks after lead-in period of 4 weeks.19
The factors that predict response to BOC/PEG-IFN/RBV were 
sought by analyzing the data from SPRINT-2 and RESPOND-2 
trials.14,15 In naive genotype 1 patients, low viral load (≤400,000 
IU/mL), IL-28B rs12979860 CC genotype, absence of cirrhosis, 
HCV subtype 1b, and nonblack were the independent baseline 
factors predicting SVR. Among these, IL-28B polymorphism 
was the strongest factor. On the other hand, in treatment-ex-
perienced patients, only previous relapse (vs nonresponse) was 
the significant factor associated with prediction of response. 
Moreover, decline of HCV RNA ≥1 log10 at week 4 was a strong 
predictor of achievement of SVR, and this was the on-treatment 
factor that was stronger than IL-28B polymorphism in predict-
ing response to BOC-containing regimen.20
Practically, the product labels indicate that 4-week lead-in 
phase of PEG-IFN/RBV should precede the administration of 
BOC. When the patient is naive, noncirrhotic and has geno-
type 1 infection, a response-guided therapy is recommended 
to determine the duration of triple therapy (24 or 32 weeks), 
depending on the response at specific time points; if HCV RNA 
remained detectable at any visit from week 8 up to but not 
including week 24, triple therapy should be continued until 32 
weeks (after 4-week lead-in), and additional PEG-IFN and RBV 
should be administrated for 12 weeks (total duration, 48 weeks). 
For the previous null responders to PEG-IFN/RBV or cirrhotic 
patients, 4-week lead-in period followed by 44 weeks of triple 
therapy is recommended. All treatments should be discontinued 
if HCV RNA levels ≥100 IU/mL at week 12 or detectable (≥10 
to 15 IU/mL) at week 24.21 Currently, the recommendations by 
the FDA in the United States and European Medicines Agency 
(EMA) differ in terms of BOC use for the treatment-experienced 
patients with genotype 1.22 The EMA still recommend that all 
treatment-experienced patients continue to receive fixed, 48 
weeks therapy rather than response-guided therapy.
2. Telaprevir
TVR, another first-generation NS3/4A inhibitor, demonstrated 
higher SVR rates when used in combination with PEG-IFN/RBV 
compared to standard therapy. In a clinical trial of genotype 
1 patients, TVR was administered together with PEG-IFN/RBV 
for the initial 12 weeks. The SVR rates of patients who received 
24 weeks and 48 weeks of PEG-IFN/RBV were 61% and 67%, 
respectively, which were significantly higher than 41% in those 
receiving PEG-IFN/RBV alone for 48 weeks.23 The most frequent 
adverse event associated with TVR was rash which resulted in 
higher discontinuation of therapy in TVR-based regimen than 
in PEG-IFN/RBV treatment (21% vs 11%). In a subsequent 
phase III trial (ADVANCE), patients with genotype 1 received 
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TVR and PEG-IFN/RBV for 8 or 12 weeks followed by PEG-IFN/
RBV in a response-guided manner. If extended rapid virologic 
response (eRVR), which was defined as undetectable HCV RNA 
at week 4 and 12, was achieved, treatment was stopped at week 
24 whereas patient who did not achieve eRVR continued an-
tiviral therapy until week 48. Overall, the SVR rates were 69% 
and 75% in those who received TVR for 8 weeks and 12 weeks, 
which were significantly higher than 44% in the control (PEG-
IFN/RBV alone). Of note is that the SVR rates of those who 
achieved eRVR in 8-week and 12-week TVR were 89% and 
83%, respectively.24
Retreatment with TVR-containing regimen exhibited higher 
treatment success rates in genotype 1 patients who did not 
achieve SVR with previous PEG-IFN/RBV therapy. In those pa-
tients who were given 12 weeks of TVR and 24 weeks of PEG-
IFN/RBV, the SVR rates were 51%. Similarly, patients who re-
ceived 24 weeks of TVR and 48 weeks of PEG-IFN/RBV showed 
SVR rates of 53%, which were significantly higher than 14% in 
those who were retreated with only PEG-IFN/RBV.25 The most 
common adverse event associated with TVR was rash, occurring 
in 51% of patients. In another phase III trial (REALIZE), patients 
were randomly assigned to one of three groups; triple therapy 
for 12 weeks followed by PEG-IFN/RBV for 36 weeks, lead-
in therapy with PEG-IFN/RBV for 4 weeks followed by triple 
therapy for 12 weeks and PEG-IFN/RBV for 32 weeks, standard-
of-care of 48 weeks of PEG-IFN/RBV alone for 48 weeks (con-
trol). The SVR rates were 64% and 66% in two TVR-containing 
regimens, which were significantly higher than 17% in the con-
trol group.26 As in BOC trial, TVR-based triple therapy was most 
effective in patients who showed relapse to prior PEG-IFN/RBV 
treatment, compared to partial or null response to the previous 
therapy. The SVR rates in the first two arms in REALIZE study 
were 83% and 88%, respectively, while the rates were 59% and 
54% in partial responders, 29% and 33% in null responders.26
Regarding safety of triple therapy in cirrhotic patients, 
European multicenter study of 674 genotype 1, treatment-
experienced patients who had been recruited in an early access 
program, which enabled eligible patients to receive BOC or TVR 
before marketing authorization, showed a high incidence of 
serious adverse events (40%), death and severe complications. 
The rate of erythropoietin or transfusion use reached 50.7% and 
12.1%. The independent risk factors associated with side effects 
were found to be low platelet count (≤100,000/mm3) and serum 
albumin less than 3.5 g/dL.27
The recommendation of TVR use in real clinical practice ac-
cording to FDA is that 12-week administration of TVR and 
PEG-IFN/RBV should be followed by PEG-IFN/RBV alone 
through week 24 or 48, as determined by attainment of eRVR in 
treatment-naive patients or in previous relapsers. The treatment 
duration for cirrhotic patients and partial (or null) responders 
to previous PEG-IFN/RBV might be a fixed, total 48 weeks (36 
weeks of PEG-IFN/RBV following 12-week of triple therapy).22
3. Simeprevir
At the time this article is written, the available literature pub-
lished which reports the efficacy and safety of simeprevir (SMV), 
a second-wave NS3/4A protease inhibitor, in genotype 1 treat-
ment-naive patients is a result from a phase IIb trial.28 Patients 
in SMV arms were randomly assigned to once-daily SMV (75 or 
150 mg) for 12 or 24 weeks, plus PEG-IFN and RBV. The control 
group received 48 weeks of PEG-IFN and RBV. The response-
guided therapy was applied; if HCV RNA <25 IU/mL at week 
4 and undetectable at weeks 12, 16, 20, all therapy completed 
at week 24 in SMV arms. If these criteria of RGT were not met, 
the total duration of treatment was 48 weeks. SVR rates in SMV 
arms ranged 74.7% to 86.1% which were significantly higher 
64.9% in the control group, except for the comparison between 
SMV 75 mg for 24 weeks and control. Interestingly, 79.2% 
to 86.1% of SMV-treated patients met the RGT criteria, and 
completed treatment by week 24. The SVR rates of those who 
shortened treatment duration according to RGT were 85.2% to 
95.6%. Serious adverse events occurred with similar frequency 
between SMV-arms and control. A mild, reversible hyperbiliru-
binemia without concomitant increase of aminotransferase was 
observed in SMV-treated patients. 
The results of subsequent phase III trials (QUEST-1, QUEST-2) 
are going to be published soon. In these pivotal trials, patients in 
treatment groups were given SMV 150 mg daily plus PEG-IFN/
RBV for 12 weeks, followed by PEG-IFN/RBV alone for either 
12 or 36 weeks according to the RGT criteria.29,30 The control 
group was given placebo for 12 weeks combined with PEG-IFN 
and RBV for 48 weeks. Since the trial design of QUEST-1 and -2 
was basically identical, two studies were pooled. The SVR rates 
measured at 12 weeks posttreatment in SMV arms were 80%, 
which were significantly higher than 50% in the control arm. 
It might be highlighted that 85% of patients in QUEST-1 and 
91.4% in QUEST-2 trial could shorten the treatment duration 
to 24 weeks according to RGT. The SVR rates in those who met 
RGT criteria were 91% and 86% in each trial.
Retreatment with SMV-based triple regimen increased the 
SVR rates in comparison with PEG-IFN and RBV. In a phase 
IIb trial, patients with treatment-failure to prior therapy were 
randomly assigned to SMV (100 or 150 mg, once daily) for 12, 
24, or 48 weeks plus PEG-IFN and RBV for 48 weeks.31 The 
control group was given PEG-IFN and RBV alone for 48 weeks. 
The rates of SVR were significantly higher in SMV-arms com-
pared to control irrespective of prior response; overall 61%-80% 
versus 23%; 38%-59% versus 19% in null responders; 48%-
86% versus 9% in partial responders; 77%-89% versus 37% in 
relapsers. The incidence of adverse events occurred with similar 
frequency between SMV-arms and control group. SMV 150 
mg tended to show higher SVR rates compared to 100 mg. The 
design of randomized, controlled phase III trial of SMV in com-
bination with PEG-IFN and RBV for retreatment for relapsers 
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was identical to QUEST-1 and -2. The rates of SVR measured 
at week 12 after completion of therapy were 79% in SMV-arm 
and 36% in the control. Most of the SMV-treated patients (92.7%) 
were eligible to shorten duration of therapy to 24 weeks and 
their SVR rates were 83%.32
The first approval of SMV was made in Japan in November 
2013. U.S. FDA also approved SMV for the treatment of geno-
type 1 CHC, in combination with PEG-IFN and RBV in Decem-
ber 2013.
4. Faldaprevir 
Faldaprevir (FDV), another second-wave NS3/4A protease 
inhibitor, has an advantage of once-daily dosing like simepre-
vir. In a global phase IIb trial, a total of 429 treatment-naive 
genotype 1 patients were randomized to 24 weeks of PEG-IFN/
RBV in combination of FDV 120 mg with 3 days of PEG-IFN/
RBV lead-in, FDV 240 mg with lead-in, or FDV 240 mg without 
lead-in.33 The control group was given 48 weeks of PEG-IFN 
and RBV. Regardless of lead-in period, all patients in FDV 240 
mg were again randomized either to stop treatment at week 24 
or to continue treatment until week 48 according to the pres-
ence of maintenance of rapid virologic response (mRVR) defined 
by HCV RNA <25 IU/mL at week 4 and undetectable HCV RNA 
at week 8 to 20. The SVR rates were the highest (84%) in group 
of FDV 240 mg without lead-in period. Furthermore, the SVR 
rates of patients who achieved mRVR were 92%. Unconjugated 
hyperbilirubinemia, rash, and photosensitivity were found to be 
adverse events associated with administration of FDV.
The results of two large multicenter, randomized, phase III tri-
als of FDV (STARTVerso 1 and 2) were recently presented.34,35 A 
total of 84% of FDV-treated patients achieved mRVR and could 
shorten treatment duration to 24 weeks. Among those who 
achieved mRVR, overall SVR rates were 83%.
The efficacy and safety of FDV without interferon has been 
evaluated in a phase IIb trial, where a total of 362 genotype 1 
patients were randomized to several groups of different treat-
ment duration. The SVR rates at 12 weeks after completion of 
therapy was the highest (69%) in patients who were given FDV 
120 mg once daily, deleobuvir, a nonnucleoside polymerase in-
hibitor, 600 mg twice daily, and RBV for 28 weeks.36 This result 
seems to be unsatisfactory compared with other interferon-free 
regimen, thus the combination of FDV and deleobuvir would 
not be further investigated in genotype 1 patients.
5. Asunaprevir 
Asunaprevir (ASV), a selective NS3 protease inhibitor, showed 
a potent antiviral activity when combined with PEG-IFN and 
RBV, against genotype 1 HCV. In a phase IIa study, the SVR 
rates in patients who received asunaprevir 600 mg once daily 
and PEG-IFN/RBV for 48 weeks were 92%. The dose of ASV 
was determined to be optimal at 200 mg twice daily since 600 
mg of asunaprevir had a greater frequency of transaminase 
elevations although ASV 200 mg twice daily combined with 
PEG-IFN/RBV had lower SVR rates, 83%.37 A promising result 
has been reported in a Japanese phase IIa study, where 21 null 
responders to PEG-IFN/RBV and 22 patients intolerant to or in-
eligible for PEG-IFN/RBV were given ASV and daclatasvir (DCV), 
a NS5A inhibitor, for 24 weeks. The overall SVR rates assessed 
at week 12 and 24 after completion of dual therapy were 76.7%. 
Diarrhea, nasopharyngitis, and headache were the most com-
mon adverse events and discontinuation of therapy occurred 
in two patients due to hyperbilirubinemia and transaminase 
elevation.38 In another Western phase IIa study, dual therapy 
with ASV and DCV or triple therapy with ASV, DCV, and RBV 
was not effective for genotype 1a patients who experienced 
null response to prior PEG-IFN/RBV therapy. On the contrary, 
quadruple therapy (ASV, DCV, and PEG-IFN/RBV) was effective 
nearly all genotype 1a patients with prior null response.39
All-oral, interferon-free regimen including ASV, DCV has 
been evaluated in a phase IIa study. A total of 66 treatment-
naive genotype 1 noncirrhotic CHC patients were randomly 
assigned to ASV (200 mg, twice daily), DCV (60 mg, once daily) 
and BMS-791325 (a nonnucleoside NS5B inhibitor) for 12 or 24 
weeks. The SVR rates at week 12 posttreatment were 92% and 
there was no difference of virologic response between 12 and 
24 weeks of treatment. The most frequent adverse events were 
headache, asthenia, and gastrointestinal symptoms.40
NS5A INHIBITORS
1. Daclatasvir
DCV is the first of DAA targeting against hepatitis C virus 
NS5A showing a very potent antiviral effect on several HCV 
genotypes. The overall adverse event profile is acceptable and 
its pharmacokinetics allow once-daily oral administration. Due 
to a relatively low genetic barrier of DCV, combination regi-
men including DCV and other NS3/4A, PEG-IFN/RBV, or NS5B 
drugs is recommended for the treatment of hepatitis C.41
The efficacy and safety of DCV in combination with PEG-
IFN/RBV were evaluated in treatment-naive genotype 1 patients. 
The patients receiving DCV 60 mg and PEG-IFN/RBV for 24 or 
48 weeks showed 90.0% of SVR rates, which were higher than 
66.7% in DCV 10 mg and PEG-IFN/RBV. The adverse events in 
group receiving DCV plus PEG-IFN/RBV were similar to those 
who were given PEG-IFN/RBV alone.42
The benefit of DCV is that viral resistance profile induced by 
DCV is not overlapped with other DAAs, which would suggest 
the most synergistic antiviral effect when combined with other 
kind of DAAs by suppressing the emergence of all possible mul-
tiple resistant variants.43 The data of efficacy and safety of DCV 
and other DAAs will be presented in the followings.
2. ABT-267
ABT-267 is a potent NS5A inhibitor and was recently report-
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ed to have a promising efficacy in difficult-to-treat genotype 1 
patients when combined with other DAAs. In a phase IIb trial, 
a total of 133 who had not had a response to prior standard 
therapy were randomly assigned to ABT-450 (protease inhibitor) 
with ritonavir (ABT-450/r), combined with ABT-267 or ABT-
333 (NNI NS5B inhibitor) or both for various treatment dura-
tions. Interestingly, the SVR rates across all the groups, ranged 
89% to 95%. Serious adverse events rarely occurred and the 
most common adverse events were fatigue, headache, nausea, 
and insomnia.44
NS5B INHIBITORS
1. Sofosbuvir
SOF, a nucleotide analogue NS5B polymerase inhibitor, 
received its first global approval for the treatment of chronic 
hepatitis C by the U.S. FDA in December 2013. Monotherapy 
of SOF is not recommended for treatment of CHC. The dose of 
SOF is 400 mg once daily, taken with or without food. Accord-
ing to package insert, SOF can be administered for 12 weeks in 
combination with PEG-IFN/RBV in HCV genotype 1 or 4 infec-
tion; SOF and RBV for 24 weeks is an alternative in genotype 1 
patients who are ineligible to receive an interferon-based treat-
ment. In genotype 2 and 3 infection, interferon-free regimen 
of SOF and RBV for 12 weeks and 24 weeks, respectively, is an 
option.45
Actually, SOF has opened the first window for the era of 
“interferon-free” treatment of hepatitis C. A lot of clinical trials 
of SOF are now ongoing to optimize the regimen and treatment 
duration for each HCV genotype. The approved, reduced treat-
ment duration (12 weeks) of PEG-IFN/RBV in combination with 
SOF is based on the results of phase III clinical trial called NEU-
TRINO where a total of 327 patients with genotype 1, 4, 5, or 6 
infection were recruited. The overall SVR rates were 91%, and 
genotype-specific SVR rates were 90% in genotype 1 and 96% 
in genotype 4.46
A randomized, open-label, phase II study (ATOMIC trial) 
showed that 12 weeks of SOF plus PEG-IFN/RBV was compara-
ble to 24 weeks of triple regimen. The SVR rates of patients who 
were given 12 weeks and 24 weeks of SOF/PEG-IFN/RBV were 
the same (89%). Patients who received SOF alone or SOF plus 
RBV for additional 12 weeks after triple regimen for 12 weeks 
showed SVR rates of 87%.47
Fission trial has evaluated the efficacy of SOF plus RBV 
(interferon-free regimen) for 12 weeks compared with standard 
therapy in genotype 2 or 3 infection. Between two groups, the 
SVR assessed at week 12 after completion of therapy was the 
same, 67%.46 Another randomized, phase III study (POSITRON 
trial) of genotype 2 or 3 patients who had previously discon-
tinued treatment with interferon due to adverse event or other 
reasons such as concomitant disease, unwillingness confirmed 
the efficacy of SOF plus RBV regimen. The SVR rates in these 
patients were 78% versus 0% in control group.48
As mentioned before, DCV has the potential benefit of syn-
ergistic antiviral effect when combined with other DAAs. Re-
cently, data of a multicenter, open-label study of SOF plus DCV 
were reported. Among treatment-naive or experienced patients 
with genotype 1, 2, or 3, various combinations of regimen (SOF 
plus DCV with or without RBV) and treatment duration (12 or 
24 weeks) were examined. Surprisingly, 98% of 126 previously 
untreated patients and 98% of 41 previously failed to protease 
inhibitors achieved SVR at week 12 after completion of therapy. 
The SVR rates in genotype 2 and 3 patients were 92% and 
89%, respectively. There was no pre-existing SOF resistance 
polymorphism or emergence at the end of therapy; however, 
NS5A-A30K polymorphism associated with DCV resistance was 
Fig. 1. Sustained virologic response 
(SVR) rates in patients with genotype 
1 hepatitis C virus (HCV) infection 
treated by all-oral, interferon-free 
regimens. Data were from differ-
ent studies and are therefore not 
comparable among agents (different 
inclusion criteria, different treat-
ment durations, assessment of SVR 
at different time points; week 12 or 
24). In each study, the results from 
the treatment group with the highest 
SVR were reported. ‘CC’ indicates 
IL28B rs12979860 genotype CC, and 
‘G’ indicates genotype. 
NR, nonresponse; Int, intolerant to 
pegylated interferon and ribavirin; 
Nuc, nucleos(t)ide inhibitor; RBV, 
ribavirin. *Subtype analysis included 
combined data for 12- and 24-week 
regimens.
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detected at baseline most frequently in genotype 2 patients.49
The adverse events related to SOF appear to be acceptable 
and manageable. Permanent discontinuation of therapy due 
to adverse events occurred in 1 and less than 1% of patients 
receiving SOF/RBV for 12 and 24 weeks, respectively, in 4% of 
placebo recipients, in 2% of SOF/PEG-IFN/RBV recipients and 
in 11% of PEG-IFN/RBV recipients.45 The most frequent adverse 
events in patients who received SOF/RBV were fatigue, head-
ache, nausea, insomnia, and pruritus.45 With availability of SOF-
based, interferon-free regimen for hepatitis C, patients on liver 
transplant waiting list or who have recurred HCV infection after 
transplantation are going to have more opportunities of receiv-
ing antiviral therapy without worsening liver function or graft 
rejection.
2. Perspectives of interferon-free regimen
Anti-HCV therapy is rapidly evolving and clinicians expect 
eradication of HCV on the earth within a few decades. Many 
global pharmaceutical industries are investing and developing 
new DAAs with improved efficacy and safety. The current inter-
feron-free regimens approved or under clinical trials have sub-
stantially higher SVR rates compared with standard PEG-IFN/
RBV treatment even in genotype 1 infection (Fig. 1).50-55 Lower 
treatment duration, decreased pill burden and adverse events, 
no injection and higher SVR rates are attractive for physicians 
to consider change their practice from interferon-based therapy 
to oral regimens for HCV therapy. However, it is a major limita-
tion that DAAs are very expensive. In developing countries, re-
placement of standard therapy by oral regimen would take time 
and depend on the expense of new drugs. In addition, it is still 
unknown whether these new therapy is effective for cirrhotic 
patients, the most-difficult-to treat population and long-term 
follow-up data will be needed to confirm excellent outcome 
of SVR. Development of DAAs obviously led to challenge and 
change in the paradigm of management for hepatitis C patients.
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